Medical device maker St. Jude Medical said Monday it received a warning letter from the Food and Drug Administration about manufacturing and quality-control problems at its plant in Sylmar where it makes implantable heart defibrillators.
The company said in a regulatory filing that it is working to correct the problems at its plant and does not expect the citation to affect its financial results.
The warning was expected after St. Jude announced in October that FDA inspectors had visited the plant. The staffers found inconsistencies in how the company manufactured and documented defibrillators, devices implanted in the chest to correct dangerous heart rhythms.
St. Jude said it is working to fix the problems cited by the government. Under the terms of the warning letter, the FDA will not approve any new product lines to be manufactured at the plant until the problems are corrected.
However, the company said the FDA is not asking the company to recall any of its products. St. Jude also said it can continue manufacturing and shipping products from the facility.
St. Jude, based in St. Paul, Minn., has struggled in recent years to address quality issues with wires used to attach the defibrillator to the heart.
St. Jude stopped selling its Riata wires in late 2010 because of concerns about their insulation, and it recalled the devices in late 2011. Last year the company recalled two other wires, QuickSite and QuickFlex. Around 79,000 Riata leads are implanted in U.S. patients, and the FDA ordered St. Jude to conduct a three-year study to learn more about the risk of insulation failure.
St. Jude Medical gets FDA warning about problems at Sylmar plant
This article
St. Jude Medical gets FDA warning about problems at Sylmar plant
can be opened in url
https://tigernewster.blogspot.com/2013/01/st-jude-medical-gets-fda-warning-about.html
St. Jude Medical gets FDA warning about problems at Sylmar plant
